LFB-SA
18.4.2016 15:39:14 CEST | Business Wire | Press release
Key events in 2015 :
- Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
- Two new products registered in Europe
- Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
- Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
- Turnover of €502.4 million, stable in comparison to 2014
Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In
2015, the key milestones have been successfully achieved. It has been a
historic and productive year for the future of LFB."
An unprecedented increase in capital in order to finance the group's
development
As part of the group's strategic development, LFB's
shareholder (the French State) decided in October to underwrite an
increase in LFB's share capital by €230 million. The share capital of
the company now stands at €280 million. To meet the financing needs of
LFB's development project, on 5 January 2016 LFB issued a senior bond of
€124 million. These funds will enable the construction of a 'new
generation' plant in Arras. This flagship project, representing an
investment of approximately €300 million, will enable LFB to triple its
global production capacity in 2020 with facilities aimed at
manufacturing for the whole world.
LFB is also developing its sites
in Alès (Gard) and Charlton (USA), establishing bio-production
facilities for recombinant medicines in development.
|
Consolidated earnings in €M |
2015 | 2014 | Variation 2015/2014 | |||
|
Turnover |
502.4 |
501.9 |
0.1 % |
|||
|
Gross margin |
177.6 |
195.5 |
-9.2 % |
|||
|
Research & development |
(81.3) |
(65.9) |
||||
|
Commercial costs |
(51.0) |
(48.6) |
||||
|
General costs |
(50.3) |
(48.7) |
||||
|
Other charges and |
17.0 |
(7.1) |
||||
|
Operational earnings |
12.0 |
25.2 |
||||
|
as a % of turnover |
2.4 % |
5.0 % |
||||
|
Net earnings |
0.3 |
13 |
€90.5 million* before research tax credit
2015 turnover - growth in international sales
At €502.4
million, turnover is relatively stable as compared to 2014. For the
second successive year, the group's turnover exceeded €500 million, with
the international side business continuing to grow. Despite a 3.2 %
decline in turnover in France during 2015, international sales rose by
€12.1 million (+8.7%), reaching €152 million. This figure represents 30%
of consolidated turnover (28% in 2014).
Operational earnings decline in order to finance strategy
Research
and development costs are increasing rapidly (€81.3 million), owing to
the large number of phase III trials in progress. Various strategic
projects reached significant milestones. In 2015, two new LFB products,
a 10% immunoglobulin and a fibrinogen have been subject to a mutual
recognition in procedure in Europe with the Paul Ehrlich Institute as
the referral agency. Two other recombinant products are currently at the
end of phase III. At the same time, LFB is planning to manufacture
product batches for launch, which has had an impact on earnings. In
2015, the group posted encouraging operational income (€17 million),
notably owing to its holding in the bio-tech company TG Therapeutics
Inc. The positive operational earnings (€12.0 million) is down as
compared to that of 2014 (-13.2 million) due to a decline in gross
margins and increased development costs. Despite this unprecedented
effort, net earnings remain positive at €0.3 million.
About LFB Group
LFB is a
bio-pharmaceutical company that develops, manufactures, and markets
medicinal products from living systems for the treatment of serious and
often rare diseases in the fields of Immunology, Hemostasis, Perinatal,
and Intensive Care. Currently ranked 6th worldwide in the field of
plasma-derived medicinal products, LFB Group is also among the leading
European companies in the development and production of proteins and
innovative treatments derived from bio-technologies. It employs 2,111
staff worldwide.
http://www.groupe-lfb.fr
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005971/en/
Contact:
LFB SA
Sandrine Charrières, 01.69.82.72.80
Communication
Director
charrieres@lfb.fr
or
David
Loison, 01.69.82.70.20
Financial Affairs Director
loisond@lfb.fr
or
Havas
Worldwide
Jeanne Bariller, 06.15.51.49.40
jeanne.bariller@havasww.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom